drugset / Trial / NCT00709995

A Study for Participants With Metastatic Renal Cell Carcinoma

NCT00709995

Phase 2 Completed 17 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will compare the effects of Enzastaurin plus Sunitinib versus Sunitinib alone in metastatic Renal Cell Cancer.

Timeline

Start
2008-06-30
Primary completion
2010-02-15
Completion
2018-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 125 mg Oral
Subject enzastaurin Small molecule 250 mg Oral
Background Sunitinib Small molecule 50 mg Oral

Indications